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Abstract
Background: Range of motion deficits of the lower extremity occur in about the half of the children with spastic
cerebral palsy (CP). Over time, these impairments can cause joint deformities and deviations in the children’s gait
pattern, leading to limitations in moblity. Preventing a loss of range of motion is important in order to reduce
secondary activity limitations and joint deformities. Sustained muscle stretch, imposed by orthotic management in
rest, might be an effective method of preventing a decrease in range of motion. However, no controlled study has
been performed.
Methods: A single blind randomised controlled trial will be performed in 66 children with spastic CP, divided over
three groups with each 22 participants. Two groups will be treated for 1 year with orthoses to prevent a decrease in
range of motion in the ankle (either with static or dynamic knee-ankle-foot-orthoses) and a third group will be included
as a control group and will receive usual care (physical therapy, manual stretching). Measurements will be performed at
baseline and at 3, 6, 9 and 12 months after treatment allocation. The primary outcome measure will be ankle
dorsiflexion at full knee extension, measured with a custom designed hand held dynamometer. Secondary outcome
measures will be i) ankle and knee flexion during gait and ii) gross motor function. Furthermore, to gain more insight in
the working mechanism of the orthotic management in rest, morphological parameters like achilles tendon length,
muscle belly length, muscle fascicle length, muscle physiological cross sectional area length and fascicle pennation
angle will be measured in a subgroup of 18 participants using a 3D imaging technique.
Discussion: This randomised controlled trial will provide more insight into the efficacy of orthotic management in rest
and the working mechanisms behind this treatment. The results of this study could lead to improved treatments.
Trial Registration Number: Nederlands Trial Register NTR2091
Keywords: Cerebral Palsy, Orthotic management in rest, Knee-ankle-foot orthoses, Ankle dorsiflexion range of
motion, Prevention, Gastrocnemius muscle, Muscle morphology, Growth
Background
Cerebral palsy
“Cerebral palsy (CP) describes a group of permanent dis-
orders of the development of movement and posture,
causing activity limitations that are attributed to non
progressive disturbances that occurred in the developing
fetal or infant brain. The motor disorders of cerebral
palsy are often accompanied by disturbances of sensa-
tion, perception, cognition, communication, and beha-
viour, by epilepsy, and by secondary musculoskeletal
problems” [1]. Spastic CP is the most common form of
CP (85%) [2]. Muscle spasticity is a clinical symptom
characterized by a velocity dependent resistance to pas-
sive stretch or movement [3]. At present, in developed
countries, about 2 live born children per 1000 have Cer-
ebral Palsy [4,5].
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joints are present in many children with spastic cerebral
palsy with about the half of the children having ROM
deficits in the ankle, knee and hip [6]. In clinical prac-
t i c e ,i ti sa s s u m e dt h a tar e d u c e dR O Mi naj o i n ti s
caused by a relative shortness of the muscle tendon
complex compared to the length of the bone and/or by
enhanced stiffness of the muscle tendon complex [7,8].
The Gastrocnemius muscle is often spastic in children
with CP [9]. As the Gastrocnemius muscle has origin at
the femur and his insertion at the calcaneus, this muscle
is a major determinant of the ankle and knee ROM.
The Gastrocnemius muscle was found to be shorter and
stiffer in children with CP (having reduced ankle dorsi-
flexion) compared to typical developing children [10]
and is expected to play a major role in the cause of lim-
ited ankle dorsiflexion ROM (measured at full knee
extension). This ankle dorsiflexion ROM may lead to
equinus deformities in the ankle [11]. Furthermore, a
short and stiff Gastrocnemius muscle may lead to a gait
pattern with increased ankle plantar flexion and
increased knee flexion in midstance [12,13]. Compared
to children with typical gait patterns, children with
deviated gait patterns are impaired in mobility [9] and
are metabolically less efficient and less resistant to fati-
gue during walking [14]. To prevent equinus contrac-
tures and less efficient gait patterns, it is important to
treat and prevent impaired ankle dorsiflexion [9].
Effectiveness of stretch
It is recommended not to use surgical interventions to
improve gait (and thus not to treat impaired ankle dor-
siflexion ROM by using surgical intervention) until gait
is matured [9]. Based on joint immobilization studies of
animals, it is well known that sustained muscle stretch
stimulates an increase in muscle length by addition of
sarcomeres in series [15-17]. In analogy with these
results it is expected sustained muscle stretch as treat-
ment of spastic calf muscles, will lengthen these muscles
and in particular the gastrocnemius. However, a sys-
tematic review about the effectiveness of passive stretch-
ing shows that there is conflicting evidence on whether
passive stretching can increase the ROM in a joint in
children with CP [18]. Two types of stretching were
investigated: 1) Manual stretching and 2) Sustained
muscle stretch. Manual stretching was defined as “hold-
ing the targeting joint to the available end ROM manu-
ally for a set amount of time, expressed as seconds, and
then releasing it” [18]. Sustained muscle stretch was
defined as “holding the targeting joint to the available
end ROM by mechanical means such as standing tables
or position equipment for an extended period, expressed
as minutes up to 5-7 hours a day” (a duration of 30
minutes stretching was the most commonly chosen in
the analysed studies) [18]. In this review it was con-
cluded that there appears to be only some indications
that sustained muscle stretch is preferable to increase
joint ROM in children with CP compared to manual
stretching.
Orthotic management in rest
Although sustained stretch is not an evidence based
treatment, it is often applied by the use of night splints
that are part of the general management of children
with CP [9,19,20]. “Night splints” are used during night
and/or during rest periods during the day. Therefore,
we prefer to use the term “orthotic management in rest”
instead of “night splinting”. Regarding the muscle of
interest in this study, the Gastrocnemius muscle of chil-
dren with spastic CP, sustained stretch is applied by
using knee-ankle-foot orthosis (KAFO). Static KAFOs
(with ankle and knee angle fixed) as well as dynamic
KAFOs (with ankle angle imposed by a spring allowing
movement) are used. These orthoses hold the ankle
joint at the maximal angle of dorsiflexion at full knee
extension.
U s i n gK A F O si nr e s tc o u l db em o r ee f f e c t i v ec o m -
pared to using KAFOs during active moments of the
day. It might be presumed that a KAFO with fixed knee
joints limits mobility, and therefore, will likely not be
worn during active moments of the day. Other orthoses,
like AFOs that are often used during active parts of the
day, do not necessarily stretch the Gastrocnemius Mus-
cle as the knee is allowed to flex. Knee flexion will
occur during, for example, walking and sitting. To the
best of our knowledge, Tardieu et al. [21] is the only
study that evaluates the efficacy of orthotic management
in rest in children with CP. It reports the effectiveness
of orthotic treatment at night in two children, but these
results are not confirmatory, due to the limited study
design: 1) the number of treated subjects (2) was small,
2) there was no control group, and 3) the subject’s ankle
dorsiflexion was measured in knee flexion rather than
extension which is more consistent with a measure of
the Soleus muscle length instead of the Gastrocnemius
muscle. Therefore, more research is needed to establish
whether their conclusions were correct and whether the
Gastrocnemius muscle will adapt in the same way to
sustained stretch as the Soleus muscle.D e s p i t et h e
reported limited evidence in the literature, the efficacy
of orthotic management in rest is probably considered
as general knowledge. It is supposed that a KAFO pre-
vents for reduced ankle dorsiflexion ROM when the
KAFO is worn for 6 or more hours a day.
The major aim of this study is to obtain insight in the
efficacy of orthotic management in rest to prevent a
reduction in ankle dorsiflexion at full knee extension
(clinical part of the study). Differences in the efficacy of
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pared as well.
Morphological properties
Recent literature shows that the morphological proper-
ties of muscles in children with CP differ from those
in typically developing children [22-24]. For example,
muscle belly length and muscle volume are smaller in
children with CP compared to typically developing
children [10,22,23]. A smaller fascicle length and smal-
ler muscle thickness is found as well in children with
CP [10,24]. Mostly, the medial gastrocnemius muscle
was investigated. However, very little is known about
the development of these morphological properties
during growth both in typically developing children
and children with CP [25], and the mechanisms under-
lying the decreasing ankle ROM during development
in children with CP are unknown. Such insight is
required to improve treatments for preventing reduced
ankle ROM. Since the ROM of a joint is thought to be
determined by the passive slack length (i.e. the smallest
length at which any force is exerted) of the muscle
tendon complex in relation to bone length and by the
muscle tendon complex stiffness, improved knowledge
of the changes in muscle morphology will likely pro-
vide insight into the etiology of reduced ROM. It is
expected that the passive slack length of the muscle
tendon complex will be affected by architectural vari-
ables, such as fascicle length (ℓ(fasc)), muscle belly
length (ℓm), physiological cross- sectional area (Af),
angle between fascicle and aponeurosis (g(fasc)) and ten-
don length (ℓt) [26-29]. The muscle tendon complex
stiffness is determined by the size and length of the
muscle belly fibres and by the amount and arrange-
ment of connective tissues (parallel elastic compo-
nents) of the muscle tendon complex [30].
The KAFO treatments tested in this study are
assumed to prevent the development of a reduced ankle
dorsiflexion at full knee extension by increasing the
slack length of the Gastrocnemius muscle muscle tendon
complex and by reducing the muscle tendon complex
stiffness. However, even if effective, the question
remains whether the muscle tendon complex slack
length increases due to muscle architectural changes
like increased fascicle length or due to the amount and
arrangement of connective tissues of the muscle tendon
complex or both (see Figure 1 for an overview of the
different architectural parameters that determine the
length of the medial Gastrocnemius muscle.
Therefore, the secondary aim of this study is to evalu-
ate how changes in ankle dorsiflexion are related to
morphological changes in the medial Gastrocnemius
muscle.
Hypotheses
Clinical part
We hypothesize that children with Cerebral Palsy (CP)
who are treated with a knee-ankle-foot orthosis (KAFO)
will show a smaller decline in (or even increase in)
ankle range of motion (ROM) into dorsiflexion com-
pared to children not being treated with a KAFO. In
addition, we anticipate that children who are treated
with a static KAFO will show less of a response (i.e.
they will have a larger decline or a smaller increase in
ankle ROM into dorsiflexion) when compared to chil-
dren being treated with a dynamic KAFO.
We expect that for children with CP, treatment with
either KAFO will have a less negative change in gait or
even a positive change in gait pattern. A positive change
refers to less ankle plantar flexion and less knee flexion
in midstance, compared to no KAFO treatment. The
effects are expected to be more positive in children
being treated with the dynamic KAFO compared to the
children being treated with the static KAFO.
The level of mobility (GMFM-score) of children who
are treated with either KAFO is expected to show a
smaller decline or increase compared to children who
are not treated with a KAFO. As above, the effects are
expected to be larger in children being treated with the
dynamic KAFO rather than in children being treated
with the static KAFO
Morphological part
In this study, it is hypothesized that the tendon length,
muscle belly length and fascicle length increase and the
muscle tendon complex stiffness decreases due to exposure
of the medial Gastrocnemius muscle to sustained stretch.
Figure 1 Schematic overview of the different architectural parameters that determine the length of the muscle tendon complex of
the medial Gastrocnemius muscle. Symbols are explained in the text.
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This study is approved by the Medical Ethics Committee
of the VU University Medical Center and by the Institu-
tional Review Board of the Washington University in
Saint Louis.
Participants
Criteria
The specific inclusion and exclusion criteria are shown
in Table 1. Briefly, participants are children with spastic
CP having been treated for reduced ankle dorsiflexion in
the past, but not needed to be treated at the moment
they were included into this study. Children are
excluded from the study if they have a history of surgery
of the Gastrocnemius muscle and/or Soleus muscle and/
or selective dorsal rhizotomy, if they have severe enough
morbidity or mobility limitations that prevent them
from walking far enough to complete a gait analysis, or
if they are being treated with intrathecal baclofen ther-
apy (i.e. they have a current, active pump).
Sample size calculation
Expecting a 5 degree change in ankle ROM (assumed as
clinically relevant), with a standard deviation of 4.5
degrees, a significance level (a) of 0.05 that is corrected
for comparisons between three groups using a Bonfer-
roni correction (a = 0.0167), and a power level of 80%,
13 children in each group will be sufficient. The calcula-
tion takes five repeated measurements with a correlation
coefficient of r = 0.7 into account. In this study, 66 par-
ticipants (22 in each group) will be recruited to allow
drop outs.
Recruitment procedure
Subjects will be recruited from three centers: 1) the VU
University medical center in the Netherlands (N = 18),
2) “Rehabilitation Medical Center (RMC) Groot Klim-
mendaal” in the Netherlands (N = 18) and 3) the Pedia-
tric Neurology Cerebral Palsy Center at Washington
University School of Medicine and St. Louis Children’s
Hospital in the USA (N = 30). Eligible subjects will be
identified by the physicians during clinical sessions or
from review of patient’s charts. The recruited children
and their parents will receive a letter about procedures
and content of the study, as well as an informed consent
form. The potential subjects and their caregivers will be
informed by the site investigators and physicians. Both
parents/guardians and children being 12 years old are
asked to sign and return the informed consent to agree
on voluntary participation in the study.
Setting & design
A single blind randomized controlled trial will be per-
formed at the three above mentioned centers. The parti-
cipants will be assigned into 3 different groups. In
addition to their regular treatment, two groups will be
treated with a dynamic or static KAFO for one year to
prevent for a reduction of ankle dorsiflexion at full knee
extension and one group will be included as a control
group without additional intervention. The morphologi-
cal measurements will be performed only at Dutch par-
ticipants at the VU University medical center.
Measurements will be performed at baseline and at 3,
6, 9 and 12 months after treatment allocation. In combi-
nation with those measurements, participants of the
experimental groups will have a meeting with the ortho-
tist and physician to check for complications with the
KAFO.
The assessor and analyser are blinded for treatment
allocation. The trial will be performed between January
2010 and December 2012.
Intervention/comparisons
Patients of the control group will receive their usual
care which may include ankle-foot-orthoses (AFOs) that
are worn during the day (for standing and walking), oral
baclofen therapy or other tone-reducing medications,
strength training, stretching exercises, physical therapy,
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Children must have:
1. a clinical diagnosis of unilateral or bilateral spastic CP
2. an age between 4-12 years old
3. at least 0° ankle dorsiflexion with extended knee (physical
examination)
4. a GMFCS class I, II or III
5. has been treated for reduced ankle dorsiflexion (< 5° dorsiflexion)
before the start of the study by:
a. and/or serial casting at least 3 months ago
b. and/or botulinum toxin A injections in the Gastrocnemius and/or
Soleus muscle at least 6 months ago
c. orthotic management in rest with a knee-ankle-foot orthosis to
prevent for decreasing ankle dorsiflexion
6. a stable social family situation
Children must not:
1. have had surgery of the Gastrocnemius and/or Soleus muscle
2. have had Selective Dorsal Rhizotomy
3. have had Intrathecal Baclofen therapy
4. have had Botulinum toxin A treatment in the lower extremity less than 6
months ago
5. have had casting of the lower extremity less than 3 months ago
6. have knee contractures (less than 0° knee extension)
7. have more than 20° ankle dorsiflexion at full knee extension
8. have behavioural problems (like severe mental retardation)
9. have significant sleeping problems
10. be institutionalised
11. be suffering from co-morbidity interfering with mobility that prevents
them from walking adequate distance.
12. have problems with understanding either the Dutch (for subjects in the
Netherlands) or English language
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the study will be monitored using questionnaires. Chil-
dren will drop out of the study if they need surgical
treatment (orthopaedic and neurosurgical procedures
affecting muscle tone and length), botulinum toxin A
injections in the lower extremity or serial casting treat-
ments in the lower extremity.
In addition to their usual care, patients of the experi-
mental groups will be treated for one year with a static
KAFO or with a dynamic KAFO using an Ultraflex
®
ankle power unit. Children will be asked to wear the
KAFO at least 6 hours per night. They will be allowed
to remove the KAFO during the night when the child is
seriously uncomfortable after wearing the KAFO for at
least 20 minutes or when the child wakes up at night
with complaints concerning the KAFO. When children
do not wear the KAFO for 6 hours per night, parents
will be asked to increase wearing time by asking the
child to wear the KAFO during rest activities in day
time. In case of unilateral treatment, patients will sleep
one night with and one night without a KAFO. In case
of bilateral treatment, patients will wear a KAFO alter-
nating on the right and left side each night.
Manufacturing the KAFO
The KAFO will be custom made by certified orthotists
using polyethylene or polypropylene and foam (for a
covered inside). Two transverse bars (polyethylene or
polypropylene) above and below the knee will be used
to reinforce and stiffen the KAFO. Bandages of nylon
Velcro straps will be placed at three locations: 1) as
high as possible on the thigh, 2) directly above the
patella and 3) directly below the patella. A circular foot
fixation, made of leather or soft polyethylene, will be
used for foot fixation. This circular foot fixation will be
closed with two velcro straps. One strap overlaps the
patient’s most convex part of the ankle and one strap
will overlap the patient’s foot proximal of the caput
ossis metatarsal I and V. Deformity of the patient’s foot
will be corrected by the use of an internal three point
pressure system (see Figure 2).
Static KAFO specification
T h es t a t i cK A F Ow i l lp r o v i d eaf i x e dk n e ee x t e n s i o no f
0° and a fixed ankle dorsiflexion angle of 0°.
Dynamic KAFO specification
The dynamic KAFO will also have a fixed knee exten-
sion of 0°, but will use an ultraflex
® ankle power unit
(Ultraflex Systems, Pottstown, PA, USA). The force of
the power unit that provides variable ankle dorsiflexion
angles will be set according to the prescription shown in
Figure 3.
Outcome measures
Primary outcome
To measure the maximal ankle dorsiflexion angle at full
knee extension, a Single Digital Inclinometer (Model
ACU001, Acumar, Lafayette, IN, USA) will be used.
This goniometer is attached to a torque wrench (Senso-
tork 713/6, Stahlwille, Germany). The goniometer-tor-
que wrench combination is attached to an adjustable
foot fixation. The foot fixation is constructed with a
forefoot part and a calcaneal part. The two parts can be
adjusted in rotation and in distance with respect to each
other. With the adjustment in rotation, adjustments for
fore foot adduction and supination can be made to sta-
bilize instable valgus foot deformity. With the adjust-
ment in distance, foot sizes can be accommodated from
150 to 240 mm. The calcaneal part has a heel support
(width: 45 mm) and a point to attach the torque
wrench. Both parts are equipped with Velcro straps for
foot fixation [31]. Figure 4 shows a photograph of the
Figure 2 Three point’s pressure for correction of deformity.( a)The equines correction will be performed by exerting force on the dorsal
side of the lower leg (just below the knee), on the instep of the foot and under the ball of the foot. (b)The valgus correction of the calcaneus
will be performed by a exerting a force laterally on the heel/calcaneus, laterally on the middle of the lower leg and medially on the lower leg,
just above the medial malleolus. (c) The forefoot abduction correction will be performed by exerting a medial stabilization force calcaneus and
talus and a lateral force on the calcaneus en the fifth os metatarsi. (d) The varus correction of the calcaneus will be performed by exerting force
on the medial part of the calcaneus, medially on the middle of the lower leg and laterally on the lower leg, just above the lateral malleolus. (e)
The forefoot adduction will be performed by exerting force on the tuberositas of the fifth os metatarsi, by exerting force laterally on the
calcaneus and laterally on the first metatarsal phalangeal joint.
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dorsiflexion angle will be measured as the angle between
the footplate of the foot fixation and the tibia (g(f-t)).
The children will be asked to lie prone on a bench,
with both feet overhanging the edge. The lower leg will
lie in such a way that the fibula head and the lateral
malleolus of the fibula are on the same height. The foot
will be firmly attached to the adjustable foot plate for
fixation. The ankle will be plantar flexed by the
researcher, applying an external plantar flexion moment
of 4 Nm, as measured using the toque wrench. The cor-
responding g(f-t) is measured (further described as the 4
Nm plantar flexion angle). Subsequently, this procedure
is repeated for 1 Nm plantar flexion and, 0 Nm, 1 Nm
dorsiflexion, 4 Nm dorsiflexion and 6 Nm dorsiflexion.
All measurements will be repeated six times and each
moment will be exerted for five seconds. The g(f-t) will
be read out from the inclinometer simultaneously at the
end of these 5 seconds at the target ankle joint moment.
Positive values refer to an external dorsal flexion
moment (Nm) of the dynamometer and dorsal flexion
a n g l e( ° )o ft h ea n k l ej o i n t .T h e r ew i l lb ef i v es e c o n d s
rest between each repetition and two minutes rest
between each condition. The conditions will always be
applied in the described order.
Children have to relax their muscles and will be
asked to lie quietly during the measurements. Muscle
activity will be checked using the electromyography
(EMG) signals of Tibialis anterior muscle and lateral
Gastrocnemius Muscle. The maximal voluntary muscle
contraction (MVC) will be recorded before the mea-
surements. The EMG signal will be A-D converted at
1000 Hz. After sampling, the signal will be high-pass
filtered at 20 Hz to remove movement artefacts.
Then, the signal will be normalized with respect to
the MVC-value and filtered low pass at 5 Hz. EMG
signals have to remain below 10% MVC during the
angle and moment measurements to ensure muscle
relaxation. Skin preparation and electrode placement
of EMG will be carried out according to SENIAM
guidelines [32].
The mean of the first 5 measurements for each condi-
tion in which the EMG signal remained below 10%
MVC will be used for further analysis. The results will
be used to create angle-moment plots in which, for
example, the muscle tendon complex stiffness can be
Figure 3 Manual for dynamic splint settings.
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the 0 Nm and 4 Nm (see Figure 5). A change in ankle
dorsiflexion ROM will be investigated by analysing the g
(f-t) measured with 4 Nm dorsiflexion.
In case of potential bilateral treatment, the full proce-
dure will only be performed on the participant’sm o s t
involved leg. For the other leg, only the 4 Nm condition
without EMG measurement will be performed to check
f o re x i tc r i t e r i a( s e ew i t h d r a w a lp a r a g r a p hb e l o w ) .I n
case of potential unilateral treatment, the primary out-
come measure will only be measured for the partici-
pant’s potentially treated leg.
Secondary outcome - gait analysis
Sagittal and frontal video-recordings of the patient’sg a i t
pattern will be made at 50 Hz. The subjects will walk 5
times barefoot and 5 times with shoes and AFO if
applicable, along a 10 m walkway at self-selected com-
fortable speed. Walking speed will be calculated from
the time to complete a part of the track (5 meters, mea-
sured with infra red detectors or with a stopwatch,
depending on measurement location). For follow up
measurements, the patient will be requested to walk at
baseline walking speed (within a range of ± 5%). Video
recordings of the involved leg(s) will be taken in the
sagittal and frontal plane. Three representative steps will
be chosen for the assessment of the knee angle in mid-
stance, the minimum knee angle in stance (between
midstance and second bipedal phase of foot contact)
and the ankle flexion in midstance. For the video analy-
sis, a custom-made software package will be used (the
Moxie Viewer
®, VU University Medical Center, Amster-
dam, the Netherlands, http://www.smalll.nl), and a soft-
ware tool, allowing on screen video measurements of
sagittal lower extremity joint angles [33]. For all partici-
pants, the gait related outcome measures will only be
measured in the potentially treated legs.
Figure 4 Photographic illustration of the hand held
dynamometer. The hand held dynamometer consists of an
adjustable foot fixation, a torque wrench and a goniometer. The
foot fixation has parts supporting the forefoot and calcaneus. These
parts are connected by a rod, allowing independent adjustments in
rotation and abduction/adduction. The forefoot part is equipped
with a fixation point to the table when needed (*).
Figure 5 Ankle-moment plots. This figure will be created from the
values measured with the hand held dynamometer. The dotted line
will be used to calculate the muscle tendon complex (MTC) stiffness
by calculating the slope of that line.
Maas et al. BMC Pediatrics 2012, 12:38
http://www.biomedcentral.com/1471-2431/12/38
Page 7 of 13Secondary outcome - mobility
The level of mobility will be quantified using the Gross
Motor Function Measure 66 Item Set (GMFM-66 IS)
[34] by a certified assessor. GMFM-66 IS scores will be
calculated with the corresponding software (Gross
Motor Ability Estimator version 1.0) that calculates
scores on an interval scale.
Patient characteristics
Patient characteristics will be recorded using an intake
form and will include age, gender, race, ethnicity,
weight, length, localisation of CP (uni- or bilateral) and
Gross Motor Function Classification System (GMFCS)
[35] class. To asses problematic behaviour of the child,
the strength and difficulties questionnaire (SDQ) [36]
will be filled in by the parents. In addition, questions
will also be asked about the children’s sport activities,
current therapies and other treatments, as well as pre-
ference sleeping positions.
Physical examination
Physical examination will be performed by the assessor
to evaluate the physical characteristics of the patient.
Variables to be measured are: 1) Position of the foot in
standing, 2) transmalleolar axis position [37], 3) gait pat-
tern classification according to Rodda [38] and Becher
[39], 4) ROM of the ankle and knee joints, 5) spasticity,
by measuring the angle of catch (AOC) [40] of the ankle
and knee, 5) selective motor control, using the Selective
Control Assessment of the Lower Extremity (SCALE)
[41] and 6) lower leg length. For all participants, the
physical examination related outcome measures will
only be measured in the potentially treated legs.
Protocol adherence
Web based diaries will be used to record the protocol
adherence and will be collected by a research assistant.
These diaries will be filled in during the fourth week of
each month and include questions regarding KAFO use,
KAFO-related complaints, sleeping problems, the use of
an ankle-foot orthosis (AFO) as well as questions
regarding stretching exercises performed over the last
month. Problems with KAFO use experienced by patient
and/or parents will be monitored by specific diary ques-
tions. The research assistant will call the participants at
least once a month to check if there are any problems
with the KAFO or motor function of the participant.
Reported problems will be solved as soon as possible.
Furthermore, to check the reliability of diary reported
KAFO wearing time, wearing time of the splints (for a
subgroup of 10 children, rec r u i t e da tV UU n i v e r s i t y
Medical Center) will be determined on the basis of
KAFO temperature measured using a TidBit tempera-
ture datalogger (UTBI-001, Onset Computer Corpora-
tion, Bourne, MA). The KAFO temperature will increase
d u et ob o d yh e a tw h e nt h eK A F Oi sw o r n .As a m p l eo f
KAFO temperature data will be recorded each 15
minutes during the treatment period. Parents and chil-
dren are not informed about the purpose of this
measurement.
Other
To get an indication of the sustained muscle stretch that
is applied by the KAFOs, two measurements will be
added. 1) The ankle moment at a g(f-t) of 0° to simulate
the static KAFO condition. This condition will be per-
formed before the handheld dynamometer protocol. 2)
The ankle dorsiflexion angle that could be imposed by
the dynamic KAFO will be estimated during consulta-
tion hours by the physician using a goniometer.
Morphological part
To determine muscle morphology related variables, 3D-
ultrasound imaging will be performed on the medial
Gastrocnemius muscle. This muscle, covered with an
ultrasound gel, will be scanned along it’s length (making
multiple transverse cross-section images, see Figure 6)
using a 5-cm linear array probe (12,5 MHz) of a B-
mode ultrasound device (Technos MPX, ESAOTE,
Italy). Two sets of recordings of the medial Gastrocne-
mius muscle will be made for each session. During 3D-
ultrasound measurements, the position of the probe
with a cluster marker is recorded using an active 3D
marker motion analysis system (Optotrak, Northern
Digital, Waterloo, Canada). In addition, 6 anatomical
landmarks (lateral malleolus, medial malleolus, medial
femur condyle, lateral femur condyle, medial femur epi-
condyle and lateral femur epicondyle) are recorded
before each experiment to gain an anatomical frame of
reference for post experimental 3D image reconstruc-
tion. In a prone position, the children are lying quietly
on a bench. Using the ankle dynamometer, the ankle is
fixed at g(f-t) corresponding to 0, 1 and 4 Nm net dorsal
flexion moment. Muscle activity is checked using EMG
during the ultra sound measurements as described
above in the primary outcome section.
The ultra sound images will be converted into a voxel
array and 3D-reconstructions will be calculated using a
custom made program in MATLAB software according
to the method that was described by Bénard e.a.[42].
Measurements are performed in the mid-longitudinal
fascicle plane of the medial Gastrocnemius muscle,
being perpendicular to (the tangent of) the distal apo-
neurosis of the medial Gastrocnemius muscle,s e l e c t e d
f r o mt h ev o x e la r r a y( s e eF i g u r e7 ) .T h eu s eo ft h ec o r -
rect plane is essential for minimizing measurement
errors of fascicle length, fascicle angle and muscle thick-
ness [43]. Measurements are performed five times
because this number of repetitions has been shown to
yield reliable results [43].
The following variables will be measured: tendon
length (ℓt,) muscle length (ℓm), fascicle length (ℓ(fasc)),
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aponeuroses (g(fasc)).
Using trigonometry, the following variables will be cal-
culated: length of medial Gastrocnemius muscle intra-
muscular distal (i.e. deep) and proximal (i.e. superficial
aponeuroses) (ℓa)a n dl e n g t hc o m p o n e n to ft h ep h y s i o -
logical cross-section (ℓAf, the added perpendicular dia-
meters of fascicles within the mid-longitudinal fascicle
plane, Figure 8).
In case of potential bilateral treatment, the morphologi-
cal outcome measures will only be measured on the parti-
cipant’s most involved leg. In case of potential unilateral
treatment, the morphological outcome measure will only
be measured at the participant’s potentially treated leg.
Exit criteria
Withdrawal
The investigator and/or clinician can decide to withdraw
a subject from the study for urgent medical reasons.
First, they have an ankle dorsiflexion angle with an
extended knee, measured as the angle between tibia and
footplate (g(f-t)), of 10° plantar flexion or more when an
external ankle dorsiflexion moment of 4 Nm is applied.
In such a case, the assessor will refer the child to the
clinician who will decide whether the reduction in ROM
has to be treated or not (note that the net ankle dorsi-
flexion moment of 4 Nm applied by the assessors is
lower than is typically applied in a clinical setting).
These children will not undergo follow-up measure-
ments as they will receive other treatment for impaired
ROM. Second, children have irresolvable problems with
KAFO use (pain, pressure sores, sleeping problems).
These subjects will be asked to undergo measurements
after withdrawal and will be included in the analyses.
Third, children can decide to withdraw at any time for
any reason. These children will be asked to undergo
measurements after withdrawal as well and will also be
included in the analyses.
Figure 6 Path of the ultrasound probe during scanning the medial Gastrocnemius muscle (MGM). The probe follows the path over the
black line. It starts proximal, with the probe perpendicular to the path. First, the probe will be guided from lateral to medial over the
respectively lateral and medial condyle of the femur. Then the probe will be rotated and moved to distal between the medial and lateral border
of medial Gastrocnemius muscle belly towards the distal end of the muscle belly, the Gastrocnemus muscle (GM) tendon and the calcaneus.
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The effects of orthotic management in rest on ankle
dorsiflexion at full knee extension will be evaluated as
soon as measurements have been performed on 30 chil-
dren regarding follow-up measurement of 6 months. If
the children in the control group show significantly lar-
ger g(f-t) reduction compared to the other groups, this
group will also be treated with a knee-ankle-foot ortho-
sis. If the knee-ankle-foot orthoses groups (static and/or
dynamic) show significantly larger reductions in g(f-t)
than the control group, the study will be terminated.
Randomization
Randomisation will be performed by block randomisa-
tion of 3, 6 or 9 subjects, with pre-stratification by cen-
ter. A member of the project team (AJD) not being
involved in the recruitment/inclusion procedure of the
subjects and not being involved in measurements will
randomly generate an allocation sequence before the
start of the trial to perform the randomisation. The
order of allocation of treatment will be noted by AJD
and kept in numbered sealed envelopes. After checking
the inclusion and exclusion criteria by a physician and
after receiving informed consent of the participant’s par-
ents, treatment allocation will be established by the
research assistant after opening the numbered envelope.
Subjects will be informed about their allocation after
performing their baseline measurement.
Blinding
The researchers performing the measurements and ana-
lysing the data will be blinded with respect to the treat-
ment allocation. The children and their parents will be
instructed to give no information about their treatment
to the assessors. Blinding will be evaluated at the end of
the study by asking the researchers the question: “In
Figure 7 The orientation of the mid-longitudinal fascicle plane. Three orientation items (*) were used to define the mid-longitudinal fascicle
plane of the medial Gastrocnemius muscle (MGM) (shaded plane and inset): 1) The estimate of the origin of the medial Gastrocnemius muscle (at
1/4
th of the line from medial to lateral condyle of the femur, see inset A) 2) the most distal muscle belly end, and 3) a point on the line
perpendicular to tangent to the distal aponeurosis in the transversal plane. The direction of the tangent is determined in the distal part of the
medial Gastrocnemius muscle belly exactly in between the medial Gastrocnemius muscle borders (see inset B).
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this for sure, or is this a guess?”
Statistics
Statistical analysis will be performed according to an
“intention to treat” principle. All relevant subject char-
acteristics, such as age, body weight and length, gender,
clinical diagnosis, will be described by their mean value
and standard deviation, or percentages. Differences
between groups at baseline will be tested using linear
regression techniques or Chi-square statistics. The effect
of the intervention will be analysed using a multi-level
analysis, with the primary and secondary outcome mea-
sures as dependent variables and treatment group and
time as independent variables. To test for any differ-
ences in the changes of variables between groups, a
treatment*time interaction is included as independent
variable. Analysis are adjusted for treatment site
(Amsterdam, Arnhem or St Louis). Covariates will be: 1)
KAFO wearing time, 2) lower leg growth, 3) use of an
AFO by day, 4) stretching exercises and 5) level of spas-
ticity. The a-value will be set at 0.05.
Discussion
This randomised controlled trial focuses on the effi-
cacy of orthotic management in rest in children with
CP to prevent a decline in ankle dorsiflexion at full
knee extension. Although orthotic management in rest
in children with CP is widely applied, very little is
known about the efficacy of this treatment. Therefore,
more research on the efficacy of orthotic management
in rest is needed. We decided to focus on the efficacy
of two types of KAFOs as orthotic management in rest
treatment since we expect that KAFOs will be the
most effective in preventing loss of ankle dorsiflexion
range. This expectation is based on the fact that a
KAFO, in contrast to an ankle-foot-orthosis (AFO), is
able to impose both knee extension and ankle dorsi-
flexion simultaneously. This may lead to more stretch
on the Gastrocnemius muscle which is the target mus-
cle of this study. The Gastrocnemius muscle is often
affected in children with spastic CP, having equines
[9].
To measure the efficacy of orthotic management in
rest, the ankle dorsiflexion has to be measured in a reli-
able and valid way. In order to achieve that, a custom
designed hand held dynamometer [31] is used to mea-
s u r et h ea n k l ed o r s i f l e x i o na n g l e .T h ed e v i c ea l l o w s
reproducible measurements of the ankle angle-moment
relationships [31]. This is important as ankle dorsiflex-
ion depends on the exerted dorsiflexion moment. Stan-
dardization of this measurement procedure reduces
variability of ankle moment and angle measurements
and hence increases the sensitivity to measure changes
in ROM. Furthermore, the device allows the investigator
to correct for foot deformations by using two separate
adjustable foot plates (to stabilize the talonavicular joint)
[31]. Foot deformations like equinovarus and equinoval-
gus [44] can, if not corrected, affect the ankle dorsiflex-
ion measurement results.
The custom designed hand held dynamometer also
allows us to measure morphological parameters of the
medial Gastrocnemius muscle at a standardized ankle
position during repeated measurements. By measuring
changes in the morphological parameters and changes
in ankle ROM simultaneously, we will gain insights into
the working mechanisms of orthotic management in
rest. As described in the methodological section we
obtain the morphological parameters by a 3D ultrasound
method. We decided to use this method instead of a 2D
ultrasound technique, because 3D ultrasound offers the
advantage of measuring the morphological parameters
in the mid-longitudinal fascicle plane. Previous research
has shown that measuring outside of the mid-longitudi-
nal fascicle plane leads to over or under estimation of
the results [43].
Figure 8 Measurement and calculation of muscle geometry of
medial Gastrocnemius muscle within its mid-longitudinal
fascicle plane.( A) The mid-longitudinal fascicle plane, determined
with 3D ultrasound. The medial Gastrocnemius muscle (MGM) is
covered by the subcutis (SUB) and supported by Soleus muscle (SM).
Parts of both femur (fem) and tibia (tib) are shown. The black
dotted lines define the outline of the muscle. The most distal
muscle belly end is indicated by a black arrow. The length of the
target fascicle (ℓ(fasc)) (dashed black line), centred at 2/3
rd (*) of
muscle belly length (from the origin) is measured. Muscle thickness
(ℓ(m th)) was calculated as the distance between the proximal and
the distal aponeurosis at the proximal end of the target fascicle (left
black double arrow). The fascicle-aponeurosis angle (g(fasc)) was
calculated as the mean of the angles of the fascicle with the
proximal and distal aponeurosis (black arcs). Scale bar depicts 1 cm.
(B) Schematic overview of morphological muscle parameters in the
mid-longitudinal fascicle plane of the medial Gastrocnemius muscle.
The length of the aponeurosis (ℓa) and the length of the
physiological cross-sectional area (ℓAf) will be calculated from this
model. The muscle belly length (ℓm) will be measured from the
origin at the femur condyle to the distal end of the muscle belly.
The tendon length (ℓt) will be measured from the distal muscle
belly end to the insertion at the calcaneus.
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dorsiflexion ROM) is an impairment parameters at the
body-function level of the International Classification of
Function, disability and health (ICF) [45]. Improvements
(or less decline) in this parameter do not necessarily
lead to improvements in activity level of the ICF model,
such as walking [45]). In order to better understand the
impact of orthotic management during rest on activity
level, this study will also investigate improvements in
gait and gross motor function level in response to
treatment.
In conclusion, this randomised controlled trial is
aimed to provide insight in the efficacy of orthotic man-
agement in rest on body function level (ankle dorsiflex-
ion range of motion) and activity level (gait, gross motor
function), and will provide insight in the treatment’s
underlying myological adaptive mechanisms. The results
of this study may provide indications for improved
treatment strategies for children with cerebral palsy and
in particular the use of orthoses.
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